Jacobs Levy Equity Management
LYEL icon

Jacobs Levy Equity Management’s Lyell Immunopharma LYEL Stock Holding History

Jacobs Levy Equity Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,621
Closed -$350K – 1048
2025
Q2 		$350K Buy
39,621
+11,672
+42% +$106K ﹤0.01% 927
2025
Q1 		$301K Sell
27,949
-41,316
-60% -$506K ﹤0.01% 980
2024
Q4 		$887K Buy
+69,265
New +$1.37M ﹤0.01% 730
2024
Q3 		– Sell
-1,559
Closed -$45.2K – 1013
2024
Q2 		$45.2K Buy
1,559
+130
+9% +$6.19K ﹤0.01% 942
2024
Q1 		$63.7K Buy
+1,429
New +$61.2K ﹤0.01% 921
2023
Q4 		– Sell
-16,268
Closed -$478K – 1036
2023
Q3 		$478K Buy
16,268
+11,289
+227% +$536K ﹤0.01% 809
2023
Q2 		$317K Sell
4,979
-77,611
-94% -$4.29M ﹤0.01% 871
2023
Q1 		$3.9M Buy
+82,590
New +$4.42M 0.02% 455

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management's LYEL Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Lyell Immunopharma (LYEL) in Q3 2025, closing a stake of 39,621 shares — an estimated $350K sold.

Jacobs Levy Equity Management first reported a position in LYEL in Q1 2023 and held it in 8 quarters. The position peaked at $3.9M in Q1 2023. 59 funds tracked by Wall St. Rank hold LYEL as of Q3 2025.

  • Jacobs Levy Equity Management reported no remaining Lyell Immunopharma position as of Q3 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 39,621 Lyell Immunopharma shares in Q3 2025, an estimated $350K.
  • Jacobs Levy Equity Management first reported a position in Lyell Immunopharma in Q1 2023 and held it in 8 quarters.
  • Jacobs Levy Equity Management's Lyell Immunopharma position peaked at $3.9M in Q1 2023.
  • 59 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.